Announcements Trials
Browse Landscape

Phase

Phase 3 3

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 4Plasma cell 3Breast 2Tumor-Agnostic 1Other solid neoplasm 1Gynecologic 1Genitourinary 1

Conditions

Nausea 2Multiple Myeloma 2Vomiting 1Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 178Bortezomib 100Lenalidomide 90daratumumab 47Melphalan 46Thalidomide 44pomalidomide 43Cyclophosphamide 38Calcium Dobesilate 30carfilzomib 29Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 14isatuximab 12ixazomib 11Granulocyte Colony-Stimulating Factor 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10dexamethasone acetate 9belantamab mafodotin 9Zoledronic Acid 8selinexor 7Epoetin Alfa 7fludarabine 6Etoposide 6dexamethasone 21-phosphate 5auricularum 5Mycophenolic Acid 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Olanzapine × Plasma cell × Clear all
NCT07413809 2026-02-17

Prevention of Delayed CINV After Autologous Transplant: Olanzapine-Containing Regimen vs. Dexamethasone-Containing Regimen

The Affiliated People's Hospital of Ningbo University

Phase 3 Recruiting
92 enrolled
Plasma cell

Multiple Myeloma

NCT06588413 2024-11-22

FONDO-LOW

Augusta University

Phase 3 Recruiting
172 enrolled
Plasma cell

Multiple Myeloma, Nausea

NCT02939287 2024-10-22

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Rush University Medical Center

Phase 3 Completed
52 enrolled 11 charts
Plasma cell

Nausea, Vomiting, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡